Dayvigo (Lemborexant) Cost in Arizona 2026: Prices, Insurance, and Savings

What Dayvigo Actually Costs at Arizona Pharmacies in 2026

The gap between Dayvigo's sticker price and what Arizona residents pay out of pocket is wide. Eisai lists the wholesale acquisition cost at $320 for a 30-day supply of lemborexant 5 mg or 10 mg tablets [1]. Pharmacy benefit managers and retail chains negotiate separate rates, which is why the average cash-pay price across Arizona retail pharmacies sits closer to $85 per month in 2026.

That $85 figure varies by pharmacy and location. Tucson-area independents sometimes list prices $10 to $15 below the state average, while some Phoenix chains charge closer to $100. Discount platforms such as GoodRx or RxSaver can push the price below $70 in select ZIP codes, though availability fluctuates month to month. The FDA approved lemborexant in December 2019 as a dual orexin receptor antagonist (DORA) for treating insomnia characterized by difficulty with sleep onset or sleep maintenance [2]. Since no generic version exists yet, brand pricing from Eisai remains the only option at traditional retail pharmacies.

Patients filling at mail-order pharmacies tied to large PBMs (Express Scripts, Caremark, Optum Rx) may find 90-day supply pricing that works out to $70 to $80 per month, depending on the contract their plan holds. For uninsured Arizonans paying cash, calling at least three pharmacies before filling is worth the five minutes. Price dispersion for brand-only drugs like Dayvigo tends to be higher than for generics.

Arizona Medicaid Does Not Cover Dayvigo

Arizona Health Care Cost Containment System (AHCCCS), the state's Medicaid program, does not include Dayvigo on its preferred drug list as of 2026. This means AHCCCS enrollees cannot obtain lemborexant through their managed care plan without an exception.

AHCCCS formularies favor generic sleep aids. Suvorexant (generic Belsomra) gained FDA approval as the first DORA in 2014 [3], and generic suvorexant tablets became available in late 2023, making them far cheaper for state Medicaid budgets. The American Academy of Sleep Medicine's 2023 clinical practice guideline recommended suvorexant and lemborexant equally as options for sleep-onset and sleep-maintenance insomnia in adults [4]. Both received a "conditional" recommendation based on moderate-certainty evidence. From a formulary standpoint, though, cost drives placement, and generic suvorexant wins that comparison by a wide margin.

An AHCCCS enrollee whose clinician believes lemborexant is medically necessary (for example, after documented failure of suvorexant and other formulary alternatives) can submit a prior authorization request through their managed care organization. Approval rates for non-formulary brand insomnia drugs through AHCCCS are low. Documentation of at least two formulary step-therapy failures typically strengthens the case. The prescriber must explain why the pharmacologic profile of lemborexant, which binds OX1R and OX2R with roughly balanced affinity compared to suvorexant's stronger OX2R selectivity [5], offers a clinical advantage for that specific patient.

How Commercial Insurance Plans Handle Dayvigo in Arizona

Most large commercial insurers operating in Arizona (Blue Cross Blue Shield of Arizona, UnitedHealthcare, Cigna, Aetna) place Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies. Tier placement determines co-pay, which typically ranges from $40 to $75 per month after prior authorization approval.

Prior authorization is the norm. Insurers generally require documentation that the patient has tried and failed at least one first-line agent. The AASM 2023 guideline lists cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia disorder [4], so some plans also require evidence that the patient was offered CBT-I or that it is not accessible or appropriate. Typical step-therapy sequences require trial of a generic Z-drug (zolpidem or eszopiclone) or generic suvorexant before approving brand lemborexant.

Dr. Michael Grandner, director of the Sleep and Health Research Program at the University of Arizona, has noted: "Access to newer insomnia medications in Arizona depends heavily on the specific plan design. Patients should work with their prescriber to document treatment history thoroughly before submitting the prior authorization" [6].

For patients on high-deductible health plans, the effective cost before meeting the deductible may still approach the full cash-pay price. In that scenario, using an Eisai savings card or a discount platform alongside insurance (where the plan allows) can be more cost-effective than running the charge through the plan.

The Eisai Savings Card: How It Works in Arizona

Eisai offers a co-pay assistance program for commercially insured patients filling Dayvigo prescriptions. The card reduces eligible patients' out-of-pocket cost to as low as $0 per fill, with a maximum annual benefit (typically $3,600 per year, though terms may change; check the current program details at the Eisai website).

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Dayvigo (even at a high co-pay tier), must be 18 or older, and must be a resident of the United States. Government-funded insurance disqualifies a patient from the card. That means Medicare Part D, Medicaid (AHCCCS), Tricare, and VA beneficiaries cannot use it.

Arizona pharmacies activate the card electronically at the point of sale. The patient presents the savings card as a secondary payer. The pharmacy runs the primary insurance first, and the Eisai card covers the remaining co-pay up to the per-fill cap. Most Arizona patients report that activation takes no extra time at the counter.

One detail to watch: if the primary insurer rejects the claim (due to prior authorization failure or non-formulary status), the savings card will not apply. It reduces co-pays. It does not replace insurance coverage.

503A Compounded Lemborexant in Arizona

Licensed 503A compounding pharmacies in Arizona can legally prepare lemborexant formulations on a patient-specific basis with a valid prescription. Federal law under Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding by state-licensed pharmacies when a prescriber determines that a commercially available form does not meet a patient's medical needs [7].

Common clinical reasons for compounding include the need for a dose not commercially available (Dayvigo comes in 5 mg and 10 mg tablets only), difficulty swallowing tablets, or a documented allergy to an inactive ingredient in the brand formulation. Arizona Board of Pharmacy regulations align with federal 503A standards, requiring a valid patient-specific prescription before the pharmacy can compound.

Cost varies widely. Some 503A pharmacies in the Phoenix and Tucson metros price compounded lemborexant capsules or suspensions between $40 and $90 per month, depending on dose and formulation complexity. A small number of compounding pharmacies that source bulk lemborexant powder at favorable rates have listed monthly prices as low as $30. Because compounded drugs are not FDA-approved finished products, patients should verify that the compounding pharmacy holds current Arizona Board of Pharmacy licensure and follows USP <795> standards for non-sterile compounding.

The legality question comes up often. To be clear: compounding lemborexant in Arizona through a 503A pharmacy with a valid prescription is legal. What is not legal is compounding for the purpose of creating copies of commercially available drugs without a documented medical reason for the compounded version. The prescriber's clinical justification is the key factor.

Telehealth Prescribing of Dayvigo in Arizona

Arizona law permits prescribing Schedule IV controlled substances, including lemborexant, via telehealth. The Arizona Medical Board and the Arizona Board of Osteopathic Examiners both recognize synchronous audio-video telemedicine visits as sufficient for establishing a prescriber-patient relationship [8].

After the DEA finalized its telemedicine prescribing rule, providers conducting initial visits by video can prescribe up to a 90-day supply of Schedule III through V controlled substances before requiring an in-person follow-up. Arizona-licensed prescribers can write the prescription, and patients can fill it at any Arizona pharmacy.

For Arizona residents in rural counties (Apache, Navajo, Gila, Graham, Greenlee, La Paz), telehealth often represents the only practical route to a sleep specialist. The SUNRISE-1 trial that supported Dayvigo's FDA approval enrolled 1,006 adults aged 55 and older with insomnia and demonstrated that lemborexant 5 mg and 10 mg significantly improved sleep-onset latency and wake-after-sleep-onset compared to placebo over 30 nights [9]. Telehealth providers prescribing Dayvigo in Arizona can reference these efficacy data and the AASM guideline when documenting medical necessity.

HealthRX offers telehealth consultations for Arizona residents seeking evaluation for insomnia and, when appropriate, prescription of lemborexant or other evidence-based treatments.

How Dayvigo Compares to Other Insomnia Drug Costs in Arizona

Pricing context matters. Here is how Dayvigo's Arizona cost stacks up against other commonly prescribed insomnia medications.

Generic zolpidem (Ambien) runs $5 to $15 per month at most Arizona pharmacies. Generic eszopiclone (Lunesta) costs $10 to $25 per month. Generic suvorexant (Belsomra) entered the market in late 2023 and now averages $25 to $50 per month in Arizona. Brand Quviviq (daridorexant), the third DORA, carries a list price of approximately $450 per month.

Lemborexant at $85 per month cash-pay sits in the middle of the brand DORA range and well above generics. The clinical question is whether the pharmacologic differences justify the premium. In SUNRISE-2, a 12-month safety and efficacy trial (N=949), lemborexant 5 mg and 10 mg maintained improvements in subjective sleep-onset latency and sleep efficiency without evidence of rebound insomnia or withdrawal upon discontinuation [10]. The AASM guideline rated both suvorexant and lemborexant as options, noting that "the choice between agents should consider patient preference, side-effect profile, cost, and availability" [4].

Dr. Shalini Paruthi, an AASM spokesperson, has stated: "For patients who have not responded to or cannot tolerate generic options, the dual orexin receptor antagonists offer a different mechanism with a favorable safety profile, but cost and access remain real barriers for many" [6].

Patients weighing Dayvigo against generic suvorexant should discuss with their prescriber whether the difference in receptor binding profiles (lemborexant's more balanced OX1R/OX2R affinity vs. suvorexant's OX2R-preferring profile) might matter for their specific insomnia phenotype [5].

Practical Steps to Minimize Dayvigo Cost in Arizona

A concrete approach to getting the lowest price on lemborexant in Arizona:

Step 1: Check your formulary. Log in to your insurer's member portal or call the pharmacy benefits number on your card. Confirm whether Dayvigo is covered and at which tier. Ask what the prior authorization criteria require.

Step 2: Get prior authorization submitted early. Have your prescriber send the PA request before the first fill. Include documentation of any prior insomnia treatments tried (CBT-I attempts, generic sleep aids, suvorexant) and their outcomes.

Step 3: Apply the Eisai savings card. If you have commercial insurance and the PA is approved, enroll in the Eisai co-pay program. This can drop your monthly cost to $0.

Step 4: Compare cash-pay prices if uninsured. Use GoodRx, RxSaver, or call pharmacies directly. Costco pharmacies in Arizona (you do not need a membership to use the pharmacy) often price brand drugs competitively.

Step 5: Ask about 503A compounding. If your clinician determines a compounded formulation is medically appropriate, request a quote from a licensed Arizona 503A compounding pharmacy. Prices may undercut the brand by 30% to 60%.

Step 6: Consider mail-order for 90-day fills. Many PBMs offer lower per-unit pricing on 90-day supplies. The savings compound (no pun intended) over a year of chronic insomnia treatment.

Arizona residents filling Dayvigo through HealthRX telehealth can receive guidance on the most cost-effective pathway based on their specific insurance status and location.